Active Share (vs S&P 500): 99.8%
· vs QQQ: 100.0%
— share of the book that differs from index weights (higher = more active)
· ranking
Est. Qtr Return (Q2 2026 → Q3 2026):
-7.3%
· vs SPY
-9.4%
· Prev Value $11.71B
— last quarter positions weighted by this quarter price moves
· ranking
Est. QTD Return (Q3 2026 → newest close):
-1.7%
· vs SPY
-3.9%
· Latest Value $9.91B
— latest reported positions valued at quarter-to-date price moves (still in progress)
· ranking
In its Q3 2026 13F filing, RTW INVESTMENTS, LP disclosed 81 equity positions with a combined reported value of $9.91B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 43.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were PTGX ($713.07M), ARGX ($682.35M), CGON ($603.60M). By sector, the heaviest allocations are Health Care 99.0%, Industrials 0.5%.
Versus the prior quarter, RTW INVESTMENTS, LP opened 10 new positions, trimmed 12 and fully exited 13, a turnover rate of 37.2% of positions. The portfolio's overlap with the prior quarter was 76% of names.
The largest new positions opened in Q3 2026 were VRDN ($102.03M), ANIX ($28.06M), PYXS ($15.16M).
Of the 13 positions fully exited versus the prior quarter, the largest were ALKS ($87.62M), DFTX ($18.82M), IDYA ($13.80M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
RTW Investments, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 81 positions worth $9.91B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Regulatory AUM (Form ADV): $14.14B as of 2026-03-30
Client mix (by RAUM): pension and profit-sharing plans 100%
Manages 3 private funds, of which 2 hedge funds
Website: rtwfunds.com
Portfolio Structure
81 positions · $9.91B reported value (Q3 2026)
Top 10 holdings = 43.5% of reported value
Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 7.2%
Average position size: $122.34M
Sector Tilt
Health Care 99.0%
Industrials 0.5%
Information Technology 0.5%
(classified holdings cover 100% of value)
Quarterly Activity
Q3 2026: 10 new, 17 added, 12 reduced, 13 exited
42 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
1. Overall direction and market view: The fund increased exposure to biotech/healthcare (all top-10 holdings are Health Care), with net additions (4 adds vs. 3 reductions in top-10), suggesting bullish sentiment on innovative therapeutics. Weight increases in most holdings indicate confidence in pipeline catalysts or sector momentum.
2. Key moves:
- Added: IRTC (+42.9% shares), TNGX (+1.1% shares), ERAS (+25.1% shares), TARS (+3.8% shares).
- Reduced: INSM (-36.1% shares), SYRE (-13.2% shares), RDNT (-4.5% shares).
- No change: PTGX, ARGX, CGON (held steady).
3. Portfolio structure: Active, high-conviction (concentrated top-10 holdings = 36.47% of AUM), with heavy bias toward clinical-stage biotech (elevated risk/reward).
4. Per-holding one-liner:
- PTGX: Protagonist Therapeutics (unverified) – peptide-based therapeutics.
- ARGX: Argenx (unverified) – autoimmune disease treatments.
- CGON: CG Oncology (unverified) – immuno-oncology therapies.
- IRTC: iRhythm (unverified) – wearable cardiac monitoring.
- INSM: Insmed (unverified) – rare lung disease drugs.
- TNGX: Tango Therapeutics (unverified) – oncology targeted therapies.
- ERAS: Erasca (unverified) – cancer drug development.
- SYRE: Spyre Therapeutics (unverified) – immunology pipeline.
- RDNT: Radnet (unverified) – diagnostic imaging services.
- TARS: Tarsus Pharmaceuticals (unverified) – eye disease treatments.
5. Style summary: Aggressive biotech fund with selective additions to high-growth clinical-stage names and reductions in overexposed positions.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 03:54
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q3)
P 70%R 70%F1 70%(modelled on 2026-Q2; 7/10 hit)
Low-confidence forecast
This fund replaces about 26% of its Top-10 each quarter and
backtests at F1 72% (threshold 80%).
Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-16.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.
Portfolio return-8.90%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+8.11%vs benchmark
Barra annualised vol32.4%Model estimate
Realised vol35.7%Annualised in window
Weighted beta0.70Raw exposure
Factor / specific risk62% / 38%Share of variance
Top-10 concentration96.7%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
-8.90%
Disclosed long book
QQQ synthetic benchmark
-17.01%
Liquidity-weighted constituents
Model universe, equal weight
-1.70%
Opportunity-cost reference
Excess return
+8.11%
Portfolio − benchmark
Arithmetic return sum
-8.50%
Difference vs compounded is the cross term
Weighted raw beta
0.70
Weighted holding betas
Realised volatility (annualised)
35.68%
Daily returns in window
Barra model volatility (annualised)
32.39%
Factor + specific
Factor share of variance
61.6%
Barra factors
Specific share of variance
38.4%
Stock residuals
Reported value
$3.28B
13F long US equity
2. Return attribution
The -8.50% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
+1.96%
23.1%
Momentum & Growth
3
-5.21%
-61.3%
Volatility & Tail Risk
7
-1.25%
-14.7%
Industry
12
+6.88%
81.0%
Specific
1
-10.88%
-128.1%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Kurtosis
Style
+0.96
+7.51%
+7.19%
84.6%
Health Care
Industry
+0.98
+6.98%
+6.88%
80.9%
Residual Volatility
Style
+1.46
+3.29%
+4.82%
56.8%
Size
Style
-1.25
-1.95%
+2.43%
28.6%
Non-linear Size
Style
+1.65
+1.01%
+1.66%
19.6%
Leverage (Downside Vol)
Style
-0.52
-1.71%
+0.89%
10.5%
Turnover
Style
-0.14
-4.80%
+0.69%
8.1%
Growth
Style
+0.09
+1.75%
+0.15%
1.8%
Short-term Reversal
Style
-0.11
+0.87%
-0.10%
-1.1%
Max Drawdown
Style
+0.14
-1.76%
-0.24%
-2.9%
Beta
Style
-0.17
+4.44%
-0.76%
-9.0%
Amihud Illiquidity
Style
+1.81
-0.45%
-0.81%
-9.5%
Mid Cap
Style
+1.02
-1.94%
-1.97%
-23.2%
Skewness
Style
+1.09
-4.39%
-4.81%
-56.6%
Momentum
Style
+1.31
-4.00%
-5.26%
-61.9%
Historical Volatility
Style
+0.60
-14.00%
-8.33%
-98.1%
Specific
Specific
—
—
-10.88%
-128.1%
3. Risk attribution
Annualised volatility is 32.39%; factor risk explains 61.6% of variance and specific risk 38.4%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Specific
Specific
—
38.4%
+12.42%
12.4%
Health Care
Industry
+0.98
24.0%
+7.76%
7.8%
Momentum
Style
+1.31
12.6%
+4.08%
4.1%
Size
Style
-1.25
7.9%
+2.55%
2.5%
Amihud Illiquidity
Style
+1.81
5.4%
+1.76%
1.8%
Mid Cap
Style
+1.02
4.1%
+1.32%
1.3%
Historical Volatility
Style
+0.60
3.5%
+1.15%
1.1%
Skewness
Style
+1.09
1.2%
+0.40%
0.4%
Kurtosis
Style
+0.96
1.2%
+0.39%
0.4%
Non-linear Size
Style
+1.65
1.1%
+0.37%
0.4%
Residual Volatility
Style
+1.46
0.7%
+0.23%
0.2%
Leverage (Downside Vol)
Style
-0.52
0.3%
+0.08%
0.1%
Liquidity
Style
-0.10
0.2%
+0.08%
0.1%
Industrials
Industry
+0.02
0.2%
+0.06%
0.1%
Beta
Style
-0.17
-0.5%
-0.14%
-0.1%
Max Drawdown
Style
+0.14
-0.5%
-0.16%
-0.2%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-1.25
+2.10
-3.34
Non-linear Size
+1.65
+1.68
-0.03
Mid Cap
+1.02
+0.13
+0.89
Beta
-0.17
+1.29
-1.47
Momentum
+1.31
+0.72
+0.60
Short-term Reversal
-0.11
-0.64
+0.53
Residual Volatility
+1.46
-0.40
+1.86
Historical Volatility
+0.59
+0.86
-0.27
Liquidity
-0.10
+0.11
-0.21
Amihud Illiquidity
+1.81
+1.16
+0.66
Turnover
-0.14
+0.21
-0.35
Growth
+0.09
+0.58
-0.50
Leverage (Downside Vol)
-0.52
+0.14
-0.66
Skewness
+1.09
+0.24
+0.86
Kurtosis
+0.96
+0.21
+0.74
Max Drawdown
+0.14
-0.08
+0.22
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
0.0%
73.6%
+0.00%
-22.33%
+3.83%
+16.44%
-16.44%
+16.44%
Communication Services
0.0%
2.6%
+0.00%
-17.64%
+0.01%
+0.46%
-0.46%
+0.46%
Utilities
0.0%
0.8%
+0.00%
+11.13%
-0.22%
-0.09%
+0.09%
-0.09%
Consumer Staples
0.0%
0.8%
+0.00%
+15.26%
-0.27%
-0.13%
+0.13%
-0.13%
Consumer Discretionary
0.0%
8.8%
+0.00%
+3.76%
-1.84%
-0.33%
+0.33%
-0.33%
Industrials
1.6%
11.1%
+3.77%
+4.36%
-2.05%
-0.07%
+0.06%
-0.43%
Health Care
98.4%
1.7%
-9.62%
+8.29%
+24.58%
-0.31%
-17.32%
-9.62%
Total
+23.92%
+15.95%
-33.59%
+6.28%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
PTGX
PROTAGONIST THERAPEUTICS INC
Health Care
21.73%
-11.40%
-2.48%
Hold
ARGX
ARGENX SE
Health Care
20.79%
-0.83%
-0.17%
Hold
INSM
INSMED INC
Health Care
10.77%
+7.66%
+0.83%
Reduce
TNGX
TANGO THERAPEUTICS INC
Health Care
10.68%
-3.13%
-0.33%
Add
RGEN
REPLIGEN CORP
Health Care
8.11%
-15.32%
-1.24%
Add
GH
GUARDANT HEALTH INC
Health Care
8.05%
-19.25%
-1.55%
Hold
NTRA
NATERA INC
Health Care
7.56%
-30.20%
-2.28%
Reduce
MDGL
MADRIGAL PHARMACEUTICALS INC
Health Care
4.80%
-15.87%
-0.76%
Reduce
GPCR
STRUCTURE THERAPEUTICS INC
Health Care
2.17%
-40.61%
-0.88%
Add
TSHA
TAYSHA GENE THERAPIES INC
Health Care
2.01%
-16.63%
-0.34%
Hold
DHR
DANAHER CORP DEL
Industrials
1.55%
+3.77%
+0.06%
Hold
NGNE
NEUROGENE INC
Health Care
1.28%
-16.25%
-0.21%
Add
BEAM
BEAM THERAPEUTICS INC
Health Care
0.43%
-14.36%
-0.06%
Hold
MDLN
MEDLINE INC
Health Care
0.07%
+12.88%
+0.01%
Hold
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
INSM
Health Care
10.77%
+7.66%
+0.83%
2
DHR
Industrials
1.55%
+3.77%
+0.06%
3
MDLN
Health Care
0.07%
+12.88%
+0.01%
4
BEAM
Health Care
0.43%
-14.36%
-0.06%
5
ARGX
Health Care
20.79%
-0.83%
-0.17%
6
NGNE
Health Care
1.28%
-16.25%
-0.21%
7
TNGX
Health Care
10.68%
-3.13%
-0.33%
8
TSHA
Health Care
2.01%
-16.63%
-0.34%
9
GPCR
Health Care
2.17%
-40.61%
-0.88%
10
RGEN
Health Care
8.11%
-15.32%
-1.24%
11
GH
Health Care
8.05%
-19.25%
-1.55%
12
NTRA
Health Care
7.56%
-30.20%
-2.28%
13
PTGX
Health Care
21.73%
-11.40%
-2.48%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -8.90%, versus -17.01% for the QQQ synthetic benchmark — an excess of +8.11%.
Return attribution: the largest positive style/industry contributions came from Kurtosis +7.19%, Health Care +6.88%, Residual Volatility +4.82%; the largest drags came from Historical Volatility -8.33%, Momentum -5.26%, Skewness -4.81%. Specific (stock-level) return contributed -10.88%.
Risk attribution: Barra model volatility is 32.39% annualised; factor risk explains 62% of variance and specific risk 38%. The largest factor risk sources are Health Care 24.0%, Momentum 12.6%, Size 7.9%.
Style tilt: size -1.25, momentum +1.31, volatility +0.59, liquidity -0.10; the weighted raw beta is 0.70. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+96.7 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.92%, selection +15.95% and interaction -33.59%.
Concentration: the top-10 positions are 96.7% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did RTW INVESTMENTS, LP buy in 2026-Q3?
In its 2026-Q3 13F filing, RTW INVESTMENTS, LP reported 81 equity positions worth $9.91B in aggregate; its largest disclosed positions were PTGX ($713.07M), ARGX ($682.35M), CGON ($603.60M).
How large is RTW INVESTMENTS, LP's portfolio?
RTW INVESTMENTS, LP reported $9.91B of long equity holdings across 81 positions as of 2026-Q3. Top-10 holdings account for 43.5% of reported value.
What is RTW INVESTMENTS, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/rtw-investments/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>